Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study

ClinicalTrials.gov ID: NCT03442101

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03442101. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study in Medication-naïve First Episode Psychosis Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Psychosis is a heterogeneous disorder and present treatment only works for a limited number of patients. In order to identify new therapeutic targets, this study will longitudinally characterize the underlying pathologies in those with poor treatment response using complimentary brain imaging modalities.

Study identification

NCT ID: NCT03442101
Recruitment status: Active, not recruiting
Study type: Observational
Phase: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Enrollment: 156 participants

Conditions and interventions

Conditions

Psychosis

Interventions

Patients with psychosis will be treated with known antipsychotic medication Drug

Drug

Eligibility (public fields only)

Age range: 17 Years to 35 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 1, 2018 (Actual)
Primary completion: Dec 30, 2026 (Estimated)
Completion: Dec 31, 2026 (Estimated)
Last update posted: Jan 12, 2026

2018 – 2026

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Sparks Center	Birmingham	Alabama	35294	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03442101, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 12, 2026 · Synced Nov 14, 2026